Patents by Inventor Jeffery J. Prusakiewicz

Jeffery J. Prusakiewicz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity
    Patent number: 8168656
    Abstract: The presently disclosed subject matter provides derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) that are characterized by substantially reduced cyclooxygenase inhibiting activity, yet retain the ability to interact with and modulate the activities of other polypeptides such as the class of peroxisome proliferators-activated receptors (PPARs) and ?-secretase. Also provided are methods of using the derivatives to treat pathological disorders.
    Type: Grant
    Filed: January 5, 2009
    Date of Patent: May 1, 2012
    Assignee: Vanderbilt University
    Inventors: Lawrence J. Marnett, Jeffery J. Prusakiewicz, Andrew S. Felts, Chuan Ji
  • Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity
    Publication number: 20090118290
    Abstract: The presently disclosed subject matter provides derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) that are characterized by substantially reduced cyclooxygenase inhibiting activity, yet retain the ability to interact with and modulate the activities of other polypeptides such as the class of peroxisome proliferators-activated receptors (PPARs) and ?-secretase. Also provided are methods of using the derivatives to treat pathological disorders.
    Type: Application
    Filed: January 5, 2009
    Publication date: May 7, 2009
    Inventors: Lawrence J. Marnett, Jeffery J. Prusakiewicz, Andrew S. Felts, Chuan Ji
  • Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity
    Patent number: 7491744
    Abstract: The presently disclosed subject matter provides derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) that are characterized by substantially reduced cyclooxygenase inhibiting activity, yet retain the ability to interact with and modulate the activities of other polypeptides such as the class of peroxisome proliferators-activated receptors (PPARs) and ?-secretase. Also provided are methods of using the derivatives to treat pathological disorders.
    Type: Grant
    Filed: April 26, 2005
    Date of Patent: February 17, 2009
    Assignee: Vanderbilt University
    Inventors: Lawrence J. Marnett, Jeffery J. Prusakiewicz, Andrew S. Felts, Chuan Ji
  • Compositions and methods for detecting and quantifying COX-2 activity by lipoamino acid metabolism
    Patent number: 7314709
    Abstract: A method of detecting an activity of a COX-2 enzyme in a subject that includes obtaining a sample of the subject; detecting an amino acid eicosanoid metabolite in the sample, wherein the presence of the amino acid eicosanoid metabolite indicates the activity of the COX-2 enzyme of the subject. Preferably the amino acid eicosanoid metabolite is a PGH2-Gly or HETE-Gly metabolite. The metabolite may be detected based on metabolism of a COX-2-selective substrate. Preferably, the substrate is a lipoamino acid. More preferably, the lipoamino acid is selected from NAGly, N-arachidonyl-alanine, and ?-arachidonyl aminobutuyic acid.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: January 1, 2008
    Assignee: Vanderbilt University
    Inventors: Lawrence J. Marnett, Jeffery J. Prusakiewicz, Kevin R. Kozak, Philip J. Kingsley
  • Compositions and methods for detecting and quantifying COX-2 activity by lipoamino acid metabolism
    Publication number: 20040029207
    Abstract: A method of detecting an activity of a COX-2 enzyme in a subject that includes obtaining a sample of the subject; detecting an amino acid eicosanoid metabolite in the sample, wherein the presence of the amino acid eicosanoid metabolite indicates the activity of the COX-2 enzyme of the subject. Preferably the amino acid eicosanoid metabolite is a PGH2-Gly or HETE-Gly metabolite. The metabolite may be detected based on metabolism of a COX-2-selective substrate. Preferably, the substrate is a lipoamino acid. More preferably, the lipoamino acid is selected from NAGly, N-arachidonyl-alanine, and &dgr;-arachidonyl aminobutuyic acid.
    Type: Application
    Filed: August 6, 2002
    Publication date: February 12, 2004
    Inventors: Lawrence J. Marnett, Jeffery J. Prusakiewicz, Kevin R. Kozak, Philip J. Kingsley